Trial Profile
Phase II Study of Abraxane and Gemicitabine in Patients With Advanced Adenocarcinoma Non-Small Cell Lung Cancer Progressing After First-Line Platinum-Based Chemotherapy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 31 Mar 2023
Price :
$35
*
At a glance
- Drugs Gemcitabine (Primary) ; Paclitaxel (Primary)
- Indications Adenocarcinoma; Non-small cell lung cancer
- Focus Therapeutic Use
- 25 Feb 2021 Status changed from active, no longer recruiting to completed.
- 29 Jan 2020 Planned primary completion date changed from 1 Apr 2019 to 31 Dec 2020.
- 29 Jan 2020 Status changed from recruiting to active, no longer recruiting.